Drug Profile
Vestronidase alfa - Ultragenyx Pharmaceutical
Alternative Names: Mepsevii; Recombinant beta-glucuronidase - Ultragenyx; Recombinant human beta glucuronidase; rhGUS; UX-003; Vestronidase alfa - vjbkLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Saint Louis University
- Developer Amicus Therapeutics; Ultragenyx Pharmaceutical
- Class Glucuronidases
- Mechanism of Action Glucuronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mucopolysaccharidosis VII
Most Recent Events
- 31 Dec 2021 Preregistration for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in Mexico (IV) prior to December 2021
- 31 Dec 2021 Registered for Mucopolysaccharidosis VII (In adolescents, In children, In adults) in Mexico (IV) prior to December 2021
- 09 Sep 2021 Launched for Mucopolysaccharidosis VII in Italy (IV) before September 2021